Pannash
  • About
    • Mission
    • Objectives
    • Editors
  • Non-ALCOHOLIC STEATOHEPATITIS (NASH)
    • Definitions
    • Epidemiology
    • Comorbidities
    • Pathophysiology
    • Diagnosis
    • Management
  • PPAR agonists
    • Science
    • pan-PPAR agonists
  • Resources
    • Commented Articles
    • Videos
    • Slides
  • Newsroom
My Account

Category: Expert Perspective

This is our archive page
post-thumb

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

3 March 2021, by Prof Sven Francque
post-thumb

NAFLD: a year in review

3 March 2021, by G. Bozet, MD
post-thumb

Early NASH development: myosteatosis rather than sarcopenia

3 March 2021, by G. Bozet, MD
post-thumb

Review: outcome of hepatocellular carcinoma in patients with NAFLD

1 March 2021, by G. Bozet, MD
post-thumb

Performance of non-invasive tests for the detection of advanced fibrosis in morbidly obese patients

1 March 2021, by G. Bozet, MD
post-thumb

Metabolic drivers of NAFLD

24 February 2021, by G. Bozet, MD
post-thumb

MAFLD, severe COVID-19 and the gut-liver axis

24 February 2021, by G. Bozet, MD
post-thumb

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

22 February 2021, by G. Bozet, MD
post-thumb

Sarcopenia: pathophysiological processes in NAFLD

22 February 2021, by G. Bozet, MD
post-thumb

NAFLD and T2D: A bidirectional relationship

19 February 2021, by G. Bozet, MD

Posts navigation

1 2 … 14 Next page
This website is supported by

2021 Copyright, Pannash. Powered by Beyond | Terms & Conditions | Privacy Notice

Accept terms and privacy policy
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Pannash
  • About
    • Mission
    • Objectives
    • Editors
  • Non-ALCOHOLIC STEATOHEPATITIS (NASH)
    • Definitions
    • Epidemiology
    • Comorbidities
    • Pathophysiology
    • Diagnosis
    • Management
  • PPAR agonists
    • Science
    • pan-PPAR agonists
  • Resources
    • Commented Articles
    • Slides
    • Video
  • Newsroom
  • My Account